annb0t
Top 20
KEY HIGHLIGHTS
Primary endpoint relating to synovial fluid biomarkers achieved and positive top-line results reported for the PARA_OA_008 phase 2 clinical trial (n=61). Several osteoarthritis (OA) biomarkers analysed were observed to favourably change over time in patients treated with injectable PPS (iPPS) compared to placebo. These biomarker changes provide insight into iPPS mechanisms of action as well as signals of disease modifying potential. iPPS was associated with positive changes for s...
>>> Read more: Paradigm Achieves Primary Endpoint in PARA_OA_008 Synovial Fluid Biomarker Phase 2 Clinical Trial
Primary endpoint relating to synovial fluid biomarkers achieved and positive top-line results reported for the PARA_OA_008 phase 2 clinical trial (n=61). Several osteoarthritis (OA) biomarkers analysed were observed to favourably change over time in patients treated with injectable PPS (iPPS) compared to placebo. These biomarker changes provide insight into iPPS mechanisms of action as well as signals of disease modifying potential. iPPS was associated with positive changes for s...
>>> Read more: Paradigm Achieves Primary Endpoint in PARA_OA_008 Synovial Fluid Biomarker Phase 2 Clinical Trial
